SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Pacira BioSciences, Inc. – ‘10-K’ for 12/31/23 – ‘EX-31.2’

On:  Thursday, 2/29/24, at 3:33pm ET   ·   For:  12/31/23   ·   Accession #:  1396814-24-30   ·   File #:  1-35060

Previous ‘10-K’:  ‘10-K’ on 2/28/23 for 12/31/22   ·   Latest ‘10-K’:  This Filing   ·   33 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 2/29/24  Pacira BioSciences, Inc.          10-K       12/31/23  123:17M

Annual Report   —   Form 10-K   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        10-K - Pcrx - 12.31.2023                            HTML   2.73M 
 2: EX-4.1      Instrument Defining the Rights of Security Holders  HTML     29K 
 7: EX-10.22    Material Contract                                   HTML     78K 
 8: EX-10.23    Material Contract                                   HTML    591K 
 9: EX-10.32    Material Contract                                   HTML     43K 
10: EX-10.33    Material Contract                                   HTML    121K 
11: EX-10.34    Material Contract                                   HTML    144K 
 3: EX-10.5     Material Contract                                   HTML     51K 
 4: EX-10.6     Material Contract                                   HTML     49K 
 5: EX-10.8     Material Contract                                   HTML     43K 
 6: EX-10.9     Material Contract                                   HTML     51K 
12: EX-21.1     Subsidiaries List                                   HTML     32K 
13: EX-23.1     Consent of Expert or Counsel                        HTML     32K 
17: EX-97       Clawback Policy re: Recovery of Erroneously         HTML     48K 
                Awarded Compensation                                             
14: EX-31.1     Certification -- §302 - SOA'02                      HTML     34K 
15: EX-31.2     Certification -- §302 - SOA'02                      HTML     34K 
16: EX-32.1     Certification -- §906 - SOA'02                      HTML     32K 
23: R1          Cover                                               HTML     98K 
24: R2          Audit Information                                   HTML     35K 
25: R3          Consolidated Balance Sheets                         HTML    145K 
26: R4          Consolidated Balance Sheets (Parenthetical)         HTML     51K 
27: R5          Consolidated Statements of Operations               HTML    121K 
28: R6          Consolidated Statements of Comprehensive Income     HTML     57K 
29: R7          Consolidated Statements of Stockholders' Equity     HTML    127K 
30: R8          Consolidated Statements of Cash Flows               HTML    165K 
31: R9          Description of Business                             HTML     36K 
32: R10         Summary of Significant Accounting Policies          HTML     78K 
33: R11         Recent Accounting Pronouncements                    HTML     44K 
34: R12         Revenue                                             HTML     87K 
35: R13         Flexion Acquisition                                 HTML     43K 
36: R14         Inventories                                         HTML     39K 
37: R15         Fixed Assets                                        HTML     45K 
38: R16         Leases                                              HTML     61K 
39: R17         Goodwill and Intangible Assets                      HTML     61K 
40: R18         Accrued Expenses                                    HTML     44K 
41: R19         Debt                                                HTML    101K 
42: R20         Financial Instruments                               HTML    155K 
43: R21         Stockholders' Equity                                HTML     58K 
44: R22         Stock Plans                                         HTML    144K 
45: R23         Net Income Per Share                                HTML     70K 
46: R24         Income Taxes                                        HTML    138K 
47: R25         Employee Benefit Plans                              HTML     38K 
48: R26         Contingent Consideration (Gains) Charges,           HTML     63K 
                Acquisition-Related Charges and Other                            
49: R27         Commercial Partners and Other Agreements            HTML     44K 
50: R28         Commitments and Contingencies                       HTML     52K 
51: R29         Subsequent Event                                    HTML     33K 
52: R30         Pay vs Performance Disclosure                       HTML     42K 
53: R31         Insider Trading Arrangements                        HTML     52K 
54: R32         Summary of Significant Accounting Policies          HTML    131K 
                (Policies)                                                       
55: R33         Summary of Significant Accounting Policies          HTML     60K 
                (Tables)                                                         
56: R34         Revenue (Tables)                                    HTML     78K 
57: R35         Flexion Acquisition (Tables)                        HTML     38K 
58: R36         Inventories (Tables)                                HTML     40K 
59: R37         Fixed Assets (Tables)                               HTML     46K 
60: R38         Leases (Tables)                                     HTML     61K 
61: R39         Goodwill and Intangible Assets (Tables)             HTML     56K 
62: R40         Accrued Expenses (Tables)                           HTML     44K 
63: R41         Debt (Tables)                                       HTML     78K 
64: R42         Financial Instruments (Tables)                      HTML    148K 
65: R43         Stockholders' Equity (Tables)                       HTML     53K 
66: R44         Stock Plans (Tables)                                HTML    145K 
67: R45         Net Income Per Share (Tables)                       HTML     70K 
68: R46         Income Taxes (Tables)                               HTML    135K 
69: R47         Contingent Consideration (Gains) Charges,           HTML     55K 
                Acquisition-Related Charges and Other - (Tables)                 
70: R48         Description of Business (Details)                   HTML     34K 
71: R49         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     48K 
                Schedule of Percentage of Revenue Comprised of the               
                Three Largest Wholesalers (Details)                              
72: R50         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     35K 
                Narrative (Details)                                              
73: R51         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fixed  HTML     41K 
                Assets (Details)                                                 
74: R52         REVENUE - Sales and Valuation Accruals (Details)    HTML     55K 
75: R53         REVENUE - Narrative (Details)                       HTML     37K 
76: R54         REVENUE - Schedule of Disaggregation of Net         HTML     48K 
                Product Sales (Details)                                          
77: R55         FLEXION ACQUISITION - Narrative (Details)           HTML     60K 
78: R56         FLEXION ACQUISITION - Schedule of Total             HTML     50K 
                Consideration (Details)                                          
79: R57         INVENTORIES - Components of Inventory (Details)     HTML     40K 
80: R58         FIXED ASSETS - Schedule of Major Categories         HTML     49K 
                (Details)                                                        
81: R59         FIXED ASSETS - Narrative (Details)                  HTML     46K 
82: R60         LEASES - Narrative (Details)                        HTML     39K 
83: R61         LEASES - Schedule of Operating Lease Cost and       HTML     49K 
                Other Operating Lease Information (Details)                      
84: R62         LEASES - Schedule of Maturities of Operating Lease  HTML     49K 
                Liabilities (Details)                                            
85: R63         GOODWILL AND INTANGIBLE ASSETS - Narrative          HTML     75K 
                (Details)                                                        
86: R64         GOODWILL AND INTANGIBLE ASSETS - Schedule of        HTML     55K 
                Intangible Assets (Details)                                      
87: R65         Accrued Expenses (Details)                          HTML     48K 
88: R66         DEBT - Carrying Value of Debt (Details)             HTML     54K 
89: R67         DEBT - Narrative (Details)                          HTML    244K 
90: R68         DEBT - Schedule of Debt (Details)                   HTML     63K 
91: R69         DEBT - Schedule of Interest Expense (Details)       HTML     46K 
92: R70         FINANCIAL INSTRUMENTS - Fair Value of Liabilities   HTML     85K 
                Measured on a Recurring Basis (Details)                          
93: R71         FINANCIAL INSTRUMENTS - Schedule of Investments     HTML     47K 
                Without Readily Determinable Fair Value (Details)                
94: R72         FINANCIAL INSTRUMENTS - Narrative (Details)         HTML     86K 
95: R73         FINANCIAL INSTRUMENTS - Schedule of Fair Value      HTML     42K 
                Inputs and Valuation (Details)                                   
96: R74         FINANCIAL INSTRUMENTS - Schedule of Changed in      HTML     37K 
                Contingent Consideration (Details)                               
97: R75         FINANCIAL INSTRUMENTS - Schedule of Investments at  HTML     89K 
                Amortized Cost and Fair Value (Details)                          
98: R76         STOCKHOLDERS' EQUITY - Narrative (Details)          HTML     46K 
99: R77         Stockholders' Equity - Aoci (Details)               HTML     54K 
100: R78         STOCK PLANS - Narrative (Details)                   HTML    103K  
101: R79         STOCK PLANS - Stock Incentive Plans (Details)       HTML     82K  
102: R80         STOCK PLANS - Compensation Expense (Details)        HTML     49K  
103: R81         STOCK PLANS - Stock Option Activity (Details)       HTML     92K  
104: R82         STOCK PLANS - Valuation Assumptions (Details)       HTML     55K  
105: R83         STOCK PLANS - RSU Activity (Details)                HTML     60K  
106: R84         NET INCOME PER SHARE - Calculation (Details)        HTML     86K  
107: R85         NET INCOME PER SHARE - Antidilutive Securities      HTML     45K  
                (Details)                                                        
108: R86         INCOME TAXES - Current and Deferred Income Taxes    HTML     67K  
                (Details)                                                        
109: R87         INCOME TAXES - Reconciliation of Effective Tax      HTML     92K  
                Rate (Details)                                                   
110: R88         INCOME TAXES - Narrative (Details)                  HTML     76K  
111: R89         INCOME TAXES - Deferred Tax Assets and Liabilities  HTML     60K  
                (Details)                                                        
112: R90         INCOME TAXES - Unrecognized Tax Benefits (Details)  HTML     37K  
113: R91         Employee Benefit Plans (Details)                    HTML     54K  
114: R92         Contingent Consideration (GAINS) CHARGES,           HTML     66K  
                ACQUISITION-RELATED CHARGES AND OTHER - Impairment               
                and Other (Details)                                              
115: R93         Contingent Consideration (GAINS) CHARGES,           HTML     62K  
                ACQUISITION-RELATED CHARGES AND OTHER - Narrative                
                (Details)                                                        
116: R94         Commercial Partners and Other Agreements (Details)  HTML     94K  
117: R95         Commitments and Contingencies (Details)             HTML     72K  
118: R96         Subsequent Event (Details)                          HTML     36K  
120: XML         IDEA XML File -- Filing Summary                      XML    205K  
123: XML         XBRL Instance -- pcrx-20231231_htm                   XML   3.07M  
119: EXCEL       IDEA Workbook of Financial Report Info              XLSX    255K  
19: EX-101.CAL  XBRL Calculations -- pcrx-20231231_cal               XML    301K 
20: EX-101.DEF  XBRL Definitions -- pcrx-20231231_def                XML   1.22M 
21: EX-101.LAB  XBRL Labels -- pcrx-20231231_lab                     XML   2.91M 
22: EX-101.PRE  XBRL Presentations -- pcrx-20231231_pre              XML   1.80M 
18: EX-101.SCH  XBRL Schema -- pcrx-20231231                         XSD    276K 
121: JSON        XBRL Instance as JSON Data -- MetaLinks              769±  1.14M  
122: ZIP         XBRL Zipped Folder -- 0001396814-24-000030-xbrl      Zip   1.33M

‘EX-31.2’   —   Certification — §302 – SOA’02

This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]

 C:   C: 
  Document  

Exhibit 31.2
CERTIFICATION
I, Charles A. Reinhart, III, certify that:
1.     I have reviewed this annual report on Form 10-K of Pacira BioSciences, Inc. (the “Registrant”);
2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;
4.     The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:
(a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and
5.     The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):
(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and
(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.


Date:February 29, 2024/s/ CHARLES A. REINHART, III
Charles A. Reinhart, III
Chief Financial Officer
(Principal Financial Officer)


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:2/29/248-K
For Period end:12/31/23
 List all Filings 

2 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/07/24  Pacira BioSciences, Inc.          10-Q        3/31/24   86:8.3M
 2/29/24  Pacira BioSciences, Inc.          S-8         2/29/24    4:108K

31 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

12/21/23  Pacira BioSciences, Inc.          8-K:5,7,9  12/20/23   13:467K
 9/26/23  Pacira BioSciences, Inc.          8-K:5,7,9   9/20/23   12:431K
 8/02/23  Pacira BioSciences, Inc.          10-Q        6/30/23   88:9.2M
 6/20/23  Pacira BioSciences, Inc.          8-K:5,9     6/13/23   11:282K
 5/03/23  Pacira BioSciences, Inc.          10-Q        3/31/23   86:9M
 4/03/23  Pacira BioSciences, Inc.          8-K:1,2,8   3/31/23   12:1.6M
 2/28/23  Pacira BioSciences, Inc.          10-K       12/31/22  118:16M
 6/10/22  Pacira BioSciences, Inc.          8-K:5,8,9   6/07/22   12:312K
 5/04/22  Pacira BioSciences, Inc.          10-Q        3/31/22   92:9.5M
 2/28/22  Pacira BioSciences, Inc.          10-K       12/31/21  128:17M
11/19/21  Flexion Therapeutics Inc.         8-K:1,2,3,511/19/21   13:374K                                   Toppan Merrill/FA
11/19/21  Pacira BioSciences, Inc.          8-K:1,2,8,911/19/21   12:452K                                   Toppan Merrill/FA
10/12/21  Pacira BioSciences, Inc.          8-K:1,2,7,910/11/21   17:3.7M                                   Toppan Merrill/FA
12/07/20  Pacira BioSciences, Inc.          8-K:5,9    12/04/20   13:254K
 7/10/20  Pacira BioSciences, Inc.          8-K:1,2,3,8 7/10/20   13:1.1M                                   Toppan Merrill/FA
 6/11/20  Pacira BioSciences, Inc.          8-K:5,9     6/05/20   11:331K                                   Toppan Merrill/FA
 2/21/20  Pacira BioSciences, Inc.          10-K       12/31/19  101:13M
 4/09/19  Pacira BioSciences, Inc.          8-K:2,5,8,9 4/09/19    4:190K                                   Toppan Merrill/FA
 3/05/19  Pacira BioSciences, Inc.          8-K:1,8,9   3/04/19    3:914K                                   Toppan Merrill/FA
 8/04/16  Pacira BioSciences, Inc.          10-Q        6/30/16   68:5.5M
 2/25/16  Pacira BioSciences, Inc.          10-K       12/31/15   87:10M                                    Workiva Inc Wde… FA01/FA
 7/30/15  Pacira BioSciences, Inc.          10-Q        6/30/15   72:5.7M
 4/30/15  Pacira BioSciences, Inc.          10-Q        3/31/15   69:5.9M
 7/31/14  Pacira BioSciences, Inc.          10-Q        6/30/14   68:7.8M
 6/04/14  Pacira BioSciences, Inc.          8-K:5,9     6/03/14    4:292K                                   Toppan Merrill/FA
10/31/13  Pacira BioSciences, Inc.          10-Q        9/30/13   64:6.5M                                   Workiva Inc.
 3/18/13  Pacira BioSciences, Inc.          8-K:1,5,9   3/13/13    8:584K                                   Toppan Merrill/FA
11/01/12  Pacira BioSciences, Inc.          10-Q        9/30/12   60:6.7M                                   Toppan Merrill/FA
 5/09/12  Pacira BioSciences, Inc.          10-Q        3/31/12   36:3.4M                                   Toppan Merrill/FA
 2/11/11  Pacira BioSciences, Inc.          8-K:5,9     2/08/11    3:188K                                   Donnelley … Solutions/FA
12/03/10  Pacira BioSciences, Inc.          S-1/A¶                25:7.1M                                   Donnelley … Solutions/FA
↑Top
Filing Submission 0001396814-24-000030   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Tue., May 14, 10:42:09.2pm ET